Russell G. Greig .

Biography

Dr Greig has more than 35 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of AM Pharma (The Netherlands) who recently signed an option agreement with Pfizer, Mint Solutions (The Netherlands) and Bionor (Norway). In addition, Dr Greig serves as a Board Member of Onxeo (France), as well as a Director of Tigenix (Belgium), and Ablynx (Belgium). He is also a Venture Partner at Kurma Life Sciences (France). He was previously Chairman of Syntaxin (UK) (sold to Ipsen), Novagali (France) (sold to Santen), and Isconova (Sweden) (sold to Novavax). He served as acting CEO at Genocea (US) and Isconova for an interim period. He was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.

Research Interest

Genetics